{"organizations": [], "uuid": "bd756a72fe9a5ce7d3d168ff46a53fb12848f447", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-intra-cellular-therapies-reports-q/brief-intra-cellular-therapies-reports-q4-loss-per-share-0-56-idUSASB0C89B", "country": "US", "domain_rank": 408, "title": "BRIEF-Intra-Cellular Therapies Reports Q4 Loss Per Share $0.56", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-01T14:09:00.000+02:00", "replies_count": 0, "uuid": "bd756a72fe9a5ce7d3d168ff46a53fb12848f447"}, "author": "", "url": "https://www.reuters.com/article/brief-intra-cellular-therapies-reports-q/brief-intra-cellular-therapies-reports-q4-loss-per-share-0-56-idUSASB0C89B", "ord_in_thread": 0, "title": "BRIEF-Intra-Cellular Therapies Reports Q4 Loss Per Share $0.56", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda", "sentiment": "none"}, {"name": "dec", "sentiment": "none"}, {"name": "intra-cellular therapies inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 1, 2018 / 12:12 PM / Updated 7 minutes ago BRIEF-Intra-Cellular Therapies Reports Q4 Loss Per Share $0.56 Reuters Staff March 1 (Reuters) - Intra-Cellular Therapies Inc: * INTRA-CELLULAR THERAPIES REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE * Q4 LOSS PER SHARE $0.56 * CASH, CASH EQUIVALENTS AND INVESTMENT SECURITIES TOTALED $464.3 MILLION AT DEC 31, 2017, VERSUS $384.1 MILLION AT DEC 31, 2016 * INTRA-CELLULAR THERAPIES - EXPECTS CASH, CASH EQUIVALENTS AND INVESTMENT SECURITIES TO BE USED PRIMARILY TO ADVANCE LUMATEPERONE DEVELOPMENT PROGRAM * INTEND TO SUBMIT A NEW DRUG APPLICATION FOR LUMATEPERONE FOR TREATMENT OF SCHIZOPHRENIA BY MID-2018 * PRE-NDA MEETING WITH FDA IS SCHEDULED TO BE HELD IN LATE Q1 2018 FOR LUMATEPERONE FOR TREATMENT OF SCHIZOPHRENIA Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)", "external_links": [], "published": "2018-03-01T14:09:00.000+02:00", "crawled": "2018-03-01T14:26:04.063+02:00", "highlightTitle": ""}